SEHK:2171Biotechs
CARsgen Therapeutics (SEHK:2171) Is Up 13.3% After Encouraging CAR-T Cell Therapy Results in Tough Cases
Earlier in November 2025, CARsgen Therapeutics Holdings announced updated clinical data for its allogeneic CAR-T cell therapy candidates, CT0596 and CT1190B, revealing initially favorable safety and efficacy outcomes in heavily pretreated patients with relapsed/refractory multiple myeloma and non-Hodgkin’s lymphoma.
An interesting insight is that some patients who had failed multiple previous advanced therapies achieved complete responses, highlighting the potential impact of these...